Enter at least 3 characters

Chiesi Group confirms positive trend to date for 2019

HOME > Press release > Chiesi Group...
Date: 22/08/2019

Chiesi Group confirms positive trend to date for 2019 

Chiesi, the international research-focused healthcare Group (Chiesi Group) confirms the positive trend to date for 2019. The latest available statistics reveal that, during the first six months of the year, overall revenues increased by 11.6% vs the first 6 months of 2018 and stand at € 956,8 million. These results confirm 2019 to be a year characterised by significant growth for a company which has recently celebrated a key strategic objective: B Corporation certification. “In parallel with this positive growth dynamic, Chiesi is also carrying out important investments”, commented Ugo Di Francesco, CEO of Chiesi Group, “only recently, for example, the French affiliate of Chiesi Group announced a 50 million euros investment on the industrial site of La Chaussée-Saint-Victor (Loir-et-Cher), to build a new production plant. This investment is expected to increase the number of Chiesi France employees, that now stands at 330 people, by 50 new hirings.”

Further investments are in place also in Parma in the Italian territory, where it is about to be completed the building of the new head office that covers an area of 46,300 square metres and will house around 540 people. The project is driven by three main elements: a new vision of the workplace, organised into shared offices and arranged depending on the activities carried out, with the aim of promoting and optimising teamwork; collective spaces will be enhanced to encourage a social atmosphere and people’s wellbeing, and lastly, a particular focus on environmental sustainability and energy efficiency. The total investment exceeds 50 million euros and the building is expected to be completed in 2020.

Chiesi Group closed 2018 on a high with an annual turnover of €1.768 million, an increase of more than +7.8% on the previous year (+4.8% at constant exchange rates), and EBITDA equal to €512.7. The robust health of the company is reflected by its investment in Research and Development, with R&D expenditure reaching €381.8 million in 2018, 21.6% of total sales, placing the company at the 13th place among the pharmaceutical companies in Europe for investments in Research and Development1. The Group currently has 47 active research and development projects and 54 clinical studies ongoing. The total number of employees now stands at over 5,600: people as a central focus, passion, entrepreneurial spirit, intercultural dialogue and sustainability are the values on which the company will continue to base its development in the coming years.

Please find further news in the "News" section.


1 European Commission - 2018 EU Industrial R&D investment scoreboard